


WHO AMR Products Data Analysis

1 Distribution of product type

Antibiotics :- 357

Non-traditional :- 259




2 #of products in each R&D phase

Phase I :- 284

Phase II :- 173

Phase III :-132


Preregistration :- 27



3 Route effectiveness

Distribution of products by route of administration and R&D phase:


- Most products taken through IV or Oral were in phase I
- IV was included in all of phases



4 Efficacy counts


Activity against priority pathogens across R&D :

- Phase I has the highest positive activity




5 Different levels of pathogen activity within each pathogen name

Pathogens activity : critical priority were less than other priority



6 Antibacterial class distribution

The majority of the classes are bacteriophage



7 Distribution of AMR products in phase I

Most cases & products were administrated intravenously.

Only TXA709 can be administered either intravenously or orally

